COSCIENS Biopharma Net Worth
COSCIENS Biopharma Net Worth Breakdown | CSCI |
COSCIENS Biopharma Net Worth Analysis
COSCIENS Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including COSCIENS Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of COSCIENS Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform COSCIENS Biopharma's net worth analysis. One common approach is to calculate COSCIENS Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares COSCIENS Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing COSCIENS Biopharma's net worth. This approach calculates the present value of COSCIENS Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of COSCIENS Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate COSCIENS Biopharma's net worth. This involves comparing COSCIENS Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into COSCIENS Biopharma's net worth relative to its peers.
To determine if COSCIENS Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding COSCIENS Biopharma's net worth research are outlined below:
| COSCIENS Biopharma generated a negative expected return over the last 90 days | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. | |
| The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| Latest headline from globenewswire.com: COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
Follow COSCIENS Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.08 M.Evaluate COSCIENS Biopharma's management efficiency
COSCIENS Biopharma has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6592) %, meaning that it created substantial loss on money invested by shareholders. COSCIENS Biopharma's management efficiency ratios could be used to measure how well COSCIENS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of now, COSCIENS Biopharma's Total Assets are increasing as compared to previous years. The COSCIENS Biopharma's current Total Current Assets is estimated to increase to about 15.6 M, while Non Current Assets Total are projected to decrease to under 14.5 M.COSCIENS Biopharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 2.6735 | Revenue 4.9 M | Quarterly Revenue Growth 0.041 | Revenue Per Share 3.759 | Return On Equity (0.66) |
COSCIENS Biopharma Earnings per Share Projection vs Actual
COSCIENS Biopharma Corporate Executives
Elected by the shareholders, the COSCIENS Biopharma's board of directors comprises two types of representatives: COSCIENS Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of COSCIENS. The board's role is to monitor COSCIENS Biopharma's management team and ensure that shareholders' interests are well served. COSCIENS Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, COSCIENS Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Giuliano Fratta | Senior CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.